Skip to search formSkip to main contentSkip to account menu

CP-868,596

Known as: CP-868596 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

crenolanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants
Abstract 141 Background: The clinically active FLT3 inhibitor AC220 is vulnerable in vitro to resistance-conferring mutations at… 
2011
2011
The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors.
10012 Background: 8-10% of gastrointestinal stromal tumors (GIST) have activating mutations of the platelet-derived growth factor… 
2011
2011
Abstract 5474: Optimization of a microdialysis method for evaluation of CP-868,596 penetration in glioblastoma murine models using a sensitive liquid chromatography mass spectrometry (LC-MS/MS…
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Focal amplification and gene rearrangement of the… 
2011
2011
Abstract 3601: CP-868,596, a highly potent and selective PDGFR TKI inhibits growth of PDGFRα-driven lung cancer cells
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Platelet-derived growth factor receptor… 
2011
2011
Abstract 3586: CP-868,596, a highly potent PDGFR inhibitor, inhibits phosphorylation of the imatinib-resistant PDGFRA D842V activating mutation associated with advanced GIST
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: 8-10% of gastrointestinal stromal tumors… 
2010
2010
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
Background:Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor… 
Highly Cited
2009
Highly Cited
2009
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced…
PURPOSE This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD… 
2008
2008
Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel (Doc) with or without AG-013736, a VEGF inhibitor
3549 Background: CP-868,596 (CP) is a specific inhibitor of the platelet-derived growth factor receptors (PDGFR) and axitinib (AG… 
2007
2007
Phase 1 study of CP-868,596 an oral, highly specific PDGFR inhibitor
3524 Background: CP-868,596 is an orally available, highly specific inhibitor of platelet-derived growth factor receptors (PDGFR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)